Magnetic Resonance Imaging (MRI) is considered a useful non-invasive method for cancer detection. However, MRI still has some limitations: low specificity for early-stage cancers as well as toxicity of Gadolinium ions, which were reported to accumulate in the nerve tissue and kidneys. Early cancer development and metastases monitoring are still difficult, because of the issues with permeability of contrasting agents through the blood-organ barriers. Nowadays, studies are being conducted to find the new contrasts with high magnetic moment, yet without gadolinium-induced toxicity. We propose an innovative, multimodal, high-k oxide-based contrasting nanoparticles (NPs), combining fluorescent properties of lanthanides with contrast in T1 and T2 spin relaxations. This material can facilitate both in-situ screening and visualization of tumour for fluorescence assisted biopsy or surgery. NPs used in our study were developed in the Institute of Physics, PAS. The NPs core was based on HfO2, doped with Eu ions, while Gd was used for positive control. Fluorescence was induced at 619nm, while emission was detectable at 630-650nm. The T1 and T2 relaxation times have been assessed using phantoms. Statistically significant changes were observed in T2 relaxation time. We used old rats, patients of the oncology clinic as an animal model. Prior to oral application of NPs (1mg/ml, 1ml/rat, LEC No 13/2015) the initial MRI screening of rats was performed. Weighted images T2 (3D FSE), SWI and SS-FSE were performed twice, 24 and 48 hours after IG. After imaging, tumours were surgically removed, for cytometric and pathomorphology evaluation.